Colorectal Cancer

Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Josep Tabernero, MD, PhD, discusses the potential of the antibody mixture Sym004 in mCRC, as well as other emerging trends in the management of colorectal cancer.

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

Andrew T. Chan, MD, MPH, a research fellow in the Department of Nutrition at the Harvard School of Public Health, discusses the impact of aspirin of cancer risk.

The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer (mCRC) following progression an upfront bevacizumab-containing regimen.

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

Maurie Markman, MD, offers examples of clinical trials where the interpretation of study results is worthy of considerable additional discussion or where justification for the actual conduct of the study can be called into question.

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.